Inogen, Inc (NASDAQ:INGN) has received a consensus recommendation of “Buy” from the eight analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $90.80.

INGN has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $108.00 price objective on shares of Inogen in a research note on Friday, September 1st. BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and set a $90.00 price objective on shares of Inogen in a research note on Tuesday, September 12th. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, J P Morgan Chase & Co upped their price objective on Inogen to $102.00 and gave the stock an “overweight” rating in a research note on Monday, June 26th.

Inogen (NASDAQ INGN) opened at 94.78 on Thursday. Inogen has a one year low of $50.24 and a one year high of $105.35. The stock’s 50 day moving average price is $98.16 and its 200 day moving average price is $91.25. The company has a market capitalization of $1.96 billion, a P/E ratio of 82.27 and a beta of 0.99.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.25 EPS. Equities analysts anticipate that Inogen will post $1.21 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/19/inogen-inc-ingn-given-consensus-rating-of-buy-by-analysts.html.

In related news, EVP Alison Bauerlein sold 15,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $94.93, for a total transaction of $1,423,950.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $92.45, for a total value of $231,125.00. Following the transaction, the executive vice president now directly owns 6,964 shares in the company, valued at $643,821.80. The disclosure for this sale can be found here. Insiders have sold a total of 73,667 shares of company stock valued at $7,041,641 over the last 90 days. 5.31% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. Curbstone Financial Management Corp increased its position in Inogen by 87.9% during the 3rd quarter. Curbstone Financial Management Corp now owns 22,460 shares of the medical technology company’s stock valued at $2,136,000 after buying an additional 10,505 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Inogen during the 2nd quarter valued at about $442,000. Koch Industries Inc. increased its position in Inogen by 19,485.8% during the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after buying an additional 653,747 shares in the last quarter. Verition Fund Management LLC acquired a new position in Inogen during the 2nd quarter valued at about $280,000. Finally, Piedmont Investment Advisors LLC acquired a new position in Inogen during the 2nd quarter valued at about $336,000.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.